AltruBio Inc. is a pioneering biotechnology company based in San Francisco, California, dedicated to developing first-in-class immune-modulators targeting diseases of immunology and inflammation. Founded in 2020, AltruBio Inc. leverages a world-class global team with expertise in immunology and drug development to advance biologic treatments for patients. The company's innovative approach and commitment to scientific excellence position it as a leader in the field of immune-modulators. Learn more at https://www.altrubio.com/altrubio/en.
With a focus on cutting-edge research and development, AltruBio Inc. aims to address unmet medical needs in immunology and inflammation. The company's strategic initiatives are driven by a mission to improve patient outcomes and quality of life through advanced biologic therapies. AltruBio Inc.'s robust pipeline and collaborative approach make it a promising player in the biotechnology sector.
AltruBio Inc.'s commitment to innovation and scientific rigor is evident in its approach to drug development and therapeutic solutions. The company's dedication to advancing immune-modulators highlights its potential to make significant contributions to the field of immunology and inflammation treatment.
Tip: The CEO isn't always your best path in. Data Surfer finds the champions and influencers who actually drive purchasing decisions.
| Ownership Private Company |
| Funding $225M |
B2B professionals should contact AltruBio Inc. for opportunities in biologic treatments and immune-modulators. The company's innovative approach and commitment to scientific excellence make it an attractive partner for collaborations and research initiatives in the biotechnology sector.
Sales teams selling biologic treatments, researchers seeking collaboration opportunities, and partners interested in immunology and inflammation therapeutics should reach out to AltruBio Inc.
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Connect with AltruBio Inc.